Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data

被引：0
作者：
Kim A. Papp
Melinda Gooderham
Ignacio Dei-Cas
Adriana LopezTello
Juan C. Garcia-Rodriguez
Carmen Yris Taveras
Azucena Hernández Rousselin
Alberto Lavieri
Mónica Maiolino
Delfina Guadalupe Villanueva Quintero
Lenka Rihakova
Mariano Salibe
Wilfran Pertuz
机构：
[1] K Papp Clinical Research and Probity Medical Research,SKiN Centre for Dermatology and Probity Medical Research
[2] Peterborough and Queen’s University,HIGA Presidente Perón, Servicio de Dermatología, Facultad Medicina UBA
[3] Psoriasis BsAs,undefined
[4] NEKI Servicios Medicos,undefined
[5] Vicente Guerreo,undefined
[6] DermaAdvance Center,undefined
[7] Hospital Regional Universitario Jose Maria Cabral Y Baez,undefined
[8] Hospital Roosevelt,undefined
[9] Calzada Roosevelt,undefined
[10] Private Clinic,undefined
[11] Consultorios Médicos Dr Bouzo,undefined
[12] Grupo Clínico CATEI (Centro de Atención en Enfermedades Inflamatorias) Sociedad Civil,undefined
[13] Novartis Pharmaceuticals Canada Inc.,undefined
[14] Novartis Argentina S.A.,undefined
[15] Novartis Pharma Logistics,undefined
[16] Inc.,undefined
[17] Panama,undefined
来源：
Dermatology and Therapy | 2023年 / 13卷
关键词：
Latin America; Plaque psoriasis; PURE registry; Real-world; Secukinumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：269 / 283
页数：14
相关论文
共 50 条
  • [41] Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
    Ohtsuki, Mamitaro
    Morita, Akimichi
    Abe, Masatoshi
    Takahashi, Hidetoshi
    Seko, Noriko
    Karpov, Alexander
    Shima, Tomohiro
    Papavassilis, Charis
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2014, 41 (12) : 1039 - 1046
  • [42] Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
    Rattanakaemakorn, Ploysyne
    Chevaisrakul, Parawee
    Wongpraparut, Chanisada
    Chiowchanwisawakit, Praveena
    Tovanabutra, Napatra
    Tantiwong, Pimchanok
    Amornpinyo, Warayuwadee
    Chakkavittumrong, Panlop
    Hanvivadhanakul, Punchong
    Chaiamnuay, Sumapa
    Laodheerasiri, Supapat
    Pattamadilok, Bensachee
    Choonhakarn, Charoen
    Mahakkanukrauh, Ajanee
    Aiewruengsurat, Duangkamol
    Sangmala, Siripan
    Pretikul, Nisa
    Sumethkul, Kittiwan
    Satpanich, Panchalee
    Boonsiri, Metavee
    Sangob, Naruemon
    Asawanonda, Pravit
    DERMATOLOGY AND THERAPY, 2024, 14 (12) : 3229 - 3241
  • [43] Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
    Adsit, Sandra
    Rivas Zaldivar, Enrique
    Sofen, Howard
    Dei-Cas, Ignacio
    Maldonado-Garcia, Cesar
    Penaranda, Elkin O.
    Puig, Luis
    Meng, Xiangyi
    Fox, Todd
    Guana, Adriana
    ADVANCES IN THERAPY, 2017, 34 (06) : 1327 - 1339
  • [44] Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
    Sandra Adsit
    Enrique Rivas Zaldivar
    Howard Sofen
    Ignacio Dei-Cas
    César Maldonado-García
    Elkin O. Peñaranda
    Luís Puig
    Xiangyi Meng
    Todd Fox
    Adriana Guana
    Advances in Therapy, 2017, 34 : 1327 - 1339
  • [45] In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis
    Galluzzo, Marco
    D'Adamio, Simone
    Silvaggio, Dionisio
    Lombardo, Paolo
    Bianchi, Luca
    Talamonti, Marina
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (02) : 173 - 182
  • [46] Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
    Gaojie Li
    Yuanxia Gu
    Qin Zou
    Yiyi Wang
    Yue Xiao
    Dengmei Xia
    Tongying Zhan
    Xingli Zhou
    Qian Wang
    Wei Yan
    Wei Li
    Dermatology and Therapy, 2022, 12 : 2105 - 2115
  • [47] Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
    Papp, Kim
    Menter, Alan
    Strober, Bruce
    Kricorian, Greg
    Thompson, ElizabethH. Z.
    Milmont, Cassandra E.
    Nirula, Ajay
    Klekotka, Paul
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (03) : 436 - U100
  • [48] Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
    Zheng, Jianfeng
    Chen, Wenjuan
    Yi, Xuemei
    Yu, Ning
    Ding, Yangfeng
    Gao, Yunlu
    FRONTIERS IN MEDICINE, 2023, 10
  • [49] Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study
    Okubo, Yukari
    Ohtsuki, Mamitaro
    Morita, Akimichi
    Yamaguchi, Masako
    Shima, Tomohiro
    Tani, Yumiko
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2019, 46 (03) : 186 - 192
  • [50] Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
    Li, Gaojie
    Gu, Yuanxia
    Zou, Qin
    Wang, Yiyi
    Xiao, Yue
    Xia, Dengmei
    Zhan, Tongying
    Zhou, Xingli
    Wang, Qian
    Yan, Wei
    Li, Wei
    DERMATOLOGY AND THERAPY, 2022, 12 (09) : 2105 - 2115
12345